Therapeutic Area: Oncology

Immunological Ignorance Is an Enabling Feature of the Oligo-Clonal T Cell Response to Melanoma Neoantigens

Linette et al.
Proceedings of the National Academy of Sciences
November 2019
Authors and Affiliates
Gerald P Linette 1 2 3 4, Michelle Becker-Hapak 5 6 7, Zachary L Skidmore 5 6 7, Miren Lorea Baroja 1 2 3 4, Chong Xu 1 2 3 4, Jasreet Hundal 5 6 7, David H Spencer 5 6 7, Weixuan Fu 1 2 3 4 8, Casey Cummins 1 2 3 4, Maya Robnett 1 2 3 4, Saghar Kaabinejadian 9, William H Hildebrand 9, Vincent Magrini 10 11, Ryan Demeter 5 6 7, Alexander S Krupnick 12, Obi L Griffith 5 6 7, Malachi Griffith 5 6 7, Elaine R Mardis 10 11, Beatriz M Carreno 13 2 3 4; 1Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. 2The Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. 3Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. 4Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. 5McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO 63110. 6Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110. 7Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110. 8Bioinformatics Core, Institute for Biomedical Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. 9Department of Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104. 10Institute for Genomic Medicine, Nationwide Children's Hospital, Ohio State University College of Medicine, Columbus, OH 43205. 11Department of Pediatrics, Ohio State University College of Medicine, Columbus, OH 43205. 12Department of Surgery, University of Virginia, Charlottesville, VA 22908. 13Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104; bcarreno@upenn.edu.

Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study

Mahalingam et al.
Clinical Cancer Research
November 2019
Authors and Affiliates
Mahalingam D1,2, Wilkinson GA3, Eng KH4, Fields P5, Raber P5, Moseley JL2, Cheetham K3, Coffey M3, Nuovo G6, Kalinski P4, Zhang B7, Arora SP2, Fountzilas C4; 1 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois. Mahalingam@northwestern.edu. 2 Mays Cancer Center, University of Texas Health San Antonio, San Antonio, Texas. 3 Oncolytics Biotech Inc, Calgary, Alberta, Canada. 4 Roswell Park Comprehensive Cancer Center, Buffalo, New York. 5 Adaptive Biotechnologies, Seattle, Washington. 6 Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio. 7 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.

Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes

Gros et al.
Journal of Clinical Investigation
November 2019
Authors and Affiliates
Alena Gros,1 Eric Tran,2,3 Maria R. Parkhurst,2 Sadia Ilyas,2 Anna Pasetto,4 Eric M. Groh,2 Paul F. Robbins,2 Rami Yossef,2 Andrea Garcia-Garijo,1 Carlos A. Fajardo,1 Todd D. Prickett,2 Li Jia,2 Jared J. Gartner,2 Satyajit Ray,2 Lien Ngo,2 John R. Wunderllich,2 James C. Yang,2 and Steven A. Rosenberg2 1Vall d’Hebron Institute of Oncology, Cellex Center, Barcelona, Spain. 2Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA. 3Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, Oregon, USA. 4Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.

Immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC; translational correlatives from a mature randomized phase II trial

Tang et al.
International Journal of Radiation Oncology &Biology & Physics
October 2019
Authors and Affiliates
Tang C1, Lee WC2, Reuben A3, Chang L4, Tran H3, Little L5, Gumbs C5, Wargo J6, Futreal A5, Liao Z7, Xia X4, Yi X4, Swisher SG8, Heymach JV9, Gomez D10, Zhang J11; 1 Departments of Radiation Oncology; Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston TX USA. 2 Genomic Medicine; Thoracic/Head and Neck Medical Oncology. 3 Thoracic/Head and Neck Medical Oncology. 4 Geneplus institute-Beijing, Beijing China. 5 Genomic Medicine. 6 Genomic Medicine; Surgical Oncology. 7 Departments of Radiation Oncology. 8 Thoracic Surgery. 9 Thoracic/Head and Neck Medical Oncology. Electronic address: jheymach@mdanderson.org. 10 Departments of Radiation Oncology. Electronic address: dgomez@mdanderson.org. 11 Genomic Medicine; Thoracic/Head and Neck Medical Oncology. Electronic address: jzhang20@mdanderson.org

Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies

Xu-Monette et al.
Journal for ImmunoTherapy of Cancer
October 2019
Authors and Affiliates
Xu-Monette ZY1,2, Li J2, Xia Y2, Crossley B3, Bremel RD4, Miao Y2, Xiao M2, Snyder T3, Manyam GC5, Tan X2, Zhang H2, Visco C6, Tzankov A7, Dybkaer K8, Bhagat G9, Tam W10, You H11, Hsi ED12, van Krieken JH13, Huh J14, Ponzoni M15, Ferreri AJM15, Møller MB16, Piris MA17, Winter JN18, Medeiros JT2, Xu B19, Li Y20, Kirsch I3, Young KH21,22,23; 1 Hematopathology Division, Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA. 2 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3 Adaptive Biotechnologies, Seattle, WA, USA. 4 ioGenetics LLC, Madison, WI, USA. 5 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6 San Bortolo Hospital, Vicenza, Italy. 7 Institute of Pathology and Medical Genetics, University Hospital of Basel, Basel, Switzerland. 8 Aalborg University Hospital, Aalborg, Denmark. 9 Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA. 10 Weill Medical College of Cornell University, New York, NY, USA. 11 Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China. 12 Cleveland Clinic, Cleveland, OH, USA. 13 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. 14 Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea. 15 San Raffaele H. Scientific Institute, Milan, Italy. 16 Odense University Hospital, Odense, Denmark. 17 Hospital Universitario Marqués de Valdecilla, Santander, Spain. 18 Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 19 Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, China. 20 Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 21 Hematopathology Division, Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA. ken.young@duke.edu. 22 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ken.young@duke.edu. 23 Duke University Medical Center, Duke Cancer Institute, Durham, NC, 27710, USA. ken.young@duke.edu.

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Rajan et al.
Journal for ImmunoTherapy of Cancer
October 2019
Authors and Affiliates
Rajan A1, Heery CR2, Thomas A3, Mammen AL4, Perry S3, O'Sullivan Coyne G5, Guha U3, Berman A3, Szabo E3,6, Madan RA5, Ballester LY7, Pittaluga S7, Donahue RN2, Tsai YT2, Lepone LM2, Chin K8, Ginty F9, Sood A9, Hewitt SM7, Schlom J2, Hassan R3, Gulley JL10; 1 Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10-CRC, Room 4-5330, 10 Center Drive, Bethesda, MD, 20892, USA. rajana@mail.nih.gov. 2 Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 3 Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10-CRC, Room 4-5330, 10 Center Drive, Bethesda, MD, 20892, USA. 4 Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA. 5 Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr., 13N240, Bethesda, MD, 20892, USA. 6 Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 7 Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 8 EMD Serono, Billerica, MA, USA. 9 GE Global Research Center, Niskayuna, NY, USA. 10 Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr., 13N240, Bethesda, MD, 20892, USA. gulleyj@mail.nih.gov.

Low-grade glioma harbors few CD8 t cells, which is accompanied by decreased expression of chemo- attractants, not immunogenic antigens

Weenink et al.
Scientific Reports
October 2019
Authors and Affiliates
Weenink B1, Draaisma K1, Ooi HZ1, Kros JM2, Sillevis Smitt PAE1, Debets R3, French PJ4; 1 Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 2 Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 3 Department of Medical Oncology, Laboratory of Tumor immunology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 4 Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. p.french@erasmusmc.nl.

An innate-like Vd1 gd T cell compartment in the human breast is associated with remission in triple-negative breast cancer

Wu et al.
Science Translational Medicine
October 2019
Authors and Affiliates
Wu Y1,2,3,4, Kyle-Cezar F1,2, Woolf RT1,5, Naceur-Lombardelli C6, Owen J6, Biswas D4,7, Lorenc A1, Vantourout P1,2, Gazinska P3,8, Grigoriadis A3, Tutt A3,8, Hayday A9,2; 1 Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, London SE1 9RT, UK. 2 Immunosurveillance Laboratory, Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. 3 Breast Cancer Now Research Unit, Innovation Hub, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, UK. 4 Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London WC1E 6DD, UK. 5 St John's Institute of Dermatology, King's College London, London SE1 9RT, UK. 6 KHP Cancer Biobank, Innovation Hub, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, UK. 7 Bill Lyons Informatics Centre, University College London Cancer Institute, University College London, London WC1E 6DD, UK. 8 Breast Cancer Now Research Centre, Institute of Cancer Research, London SW3 6JB, UK. 9 Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, London SE1 9RT, UK. adrian.hayday@kcl.ac.uk.

En masse discovery of anti-cancer human monoclonal antibodies by de novo assembly of immunoglobulin sequences from transcriptomes and genome sequences of cancer tissues

Zhang et al.
Cellular & Molecular Immunology
September 2019
Authors and Affiliates
Zhang P1, Chou HY1,2, Young L3, Zheng P4,5, Liu Y6,7; 1 Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA. 2 The Institute for Biomedical Sciences, The George Washington University, Washington, DC, 20037, USA. 3 Center for Cancer and Immunology Research, Children's Research Institute, Children's National Health System, Washington, DC, 20010, USA. 4 Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA. PZheng@ihv.umaryland.edu. 5 OncoImmune, Inc, Rockville, MD, 20852, USA. PZheng@ihv.umaryland.edu. 6 Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA. YaLiu@ihv.umaryland.edu. 7 OncoImmune, Inc, Rockville, MD, 20852, USA. YaLiu@ihv.umaryland.edu.

Distinct PLZF+CD8αα+ Unconventional T Cells Enriched in Liver Use a Cytotoxic Mechanism to Limit Autoimmunity

Sheng et al.
Journal of Immunology
September 2019
Authors and Affiliates
Sheng H1,2, Marrero I1,2, Maricic I1,2, Fanchiang SS1,2, Zhang S3, Sant'Angelo DB3, Kumar V4,2.; 1 Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA 92093. 2 Torrey Pines Institute for Molecular Studies, San Diego, CA 92121; and. 3 Rutgers University, New Brunswick, NJ 08901. 4 Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA 92093